<
ELIQUIS 5MG TABLETS 56`S
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ? II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
KES 27,718.00
(Inclusive of all taxes)
-
Compare
-
Share:
-
No Warranty
-
COD Avilable
-
Non Returnable
-
Non cancelable
ELIQUIS 5MG TABLETS 56`S
No FAQs Found
Related Products
